Erratum: Department of Error(S0140673612619618)(10.1016/S0140-6736(12)61961-8);Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: Results of two randomised trials

The Lancet

Volumn 381, Issue 9869, 2013, Pages 825-835

  Vesikari, Timo ^a   Esposito, Susanna ^b   Prymula, Roman ^c   Ypma, Ellen ^d   Kohl, Igor ^d   Toneatto, Daniela ^d   Dull, Peter ^d   Kimura, Alan ^d  

^a UNIVERSITY OF TAMPERE MEDICAL SCHOOL   (Finland)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^d Clinical Research and Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENINGOCOCCUS VACCINE; PNEUMOCOCCUS VACCINE;

ARTICLE; DRUG SAFETY; EUROPE; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; INTENTION TO TREAT ANALYSIS; MALE; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SERUM BACTERICIDAL ACTIVITY; TREATMENT RESPONSE; VACCINATION;

EID: 84874748687     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60629-7     Document Type: Erratum

References (32)

1. Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010; 362: 1511-20.
2. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27 (suppl 3): B51-63.
3. Sadarangani M, Pollard AJ. Serogroup B meningococcal vaccines-an unfinished story. Lancet Infect Dis 2010; 10: 112-24.
4. Snape MD, Dawson T, Oster P, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life. A randomized comparative trial. Pediatr Infect Dis J 2010; 29: e71-79.
5. Holst J, Martin D, Arnold R, et al. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis. Vaccine 2009; 27 (suppl 2): B3-12.
6. Tappero JW, Lagos R, Ballesteros AM, et al. Immunogenicity of 2 serogroup B outer-membrane protein meningococcal vaccines: a randomized controlled trial in Chile. JAMA 1999; 281: 1520-27.
7. Giuliani MM, Adu-Bobie J, Comanducci M, et al. A universal vaccine for serogroup B meningococcus. PNAS 2006; 103: 10834-39.
8. Giuliani MM, Biolchi A, Serruto D, et al. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine 2010; 28: 5023-30.
9. Serruto D, Spadafina T, Ciucchi L, et al. Neisseria meningitidis GNA2132, a heparin-binding protein that induces protective immunity in humans. PNAS 2010; 107: 3770-75.
10. Bambini S, Muzzi A, Olcen P, Rappuoli R, Pizza M, Comanducci M. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 2009; 27: 2794-803.
11. Findlow J, Borrow R, Snape MD, et al. Multicentre, open-label, randomised phase II controlled study of an investigational recombinant serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010; 51: 1127-37.
12. Gossger N, Snape MD, Yu L-M, et al. Immunogenicity and tolerability of recombinant meningococcal serogroup B vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. JAMA 2012; 307: 575-82.
13. Borrow R, Carlone GM, Rosenstein N, et al. Neisseria meningitidis group B correlates of protection and assay standardization-international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 2006; 24: 5093-107.
14. Santos GF, Giuliani M, Santini L, et al. Investigation on the effect of immune selection on resistance to bactericidal antibodies to group B meningococci in vitro. Clin Vaccine Immunol 2009; 16: 1693-95.
15. Frasch CE, Borrow R, Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009; 27 (suppl 2): B112-16.
16. Knuf M, Habermehl P, Zepp F, et al. Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Pediatr Infect Dis J 2006; 25: 12-18.
17. Newburger JW, Takahashi M, Gerber MA, et al. Diagnosis, treatment, and long-term management of Kawasaki Disease: a statement for health professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, American Heart Association. Pediatrics 2004; 114: 1708-33.
18. Marshall HS, Richmond PC, Nissen MD, et al. Safety and immunogenicity of a meningococcal B bivalent rLP2086 vaccine in healthy toddlers aged 18 to 36 months: a phase 1 randomized controlled clinical trial. Pediatr Infect Dis J 2012; 31: 1061-68.
19. Santolaya ME, O'Ryan ML, Valenzuela MT, et al. Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study. Lancet 2012; 379: 617-24.
20. Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5-year olds in New Zealand. Vaccine 2007;25: 3075-79.
21. Donnelly J, Medini D, Boccadifuoco G, et al. Qualitative and quantitative assessment of meningococcal antigens to evaluate the potential strain coverage of protein-based vaccines. PNAS 2010; 107: 19490-95.
22. Lucidarme J, Newbold LS, Findlow J, et al. Molecular targets in meningococci: efficient routine characterization and optimal outbreak investigation in conjunction with routine surveillance of the meningococcal group B vaccine candidate, fHbp. Clin Vaccine Immunol 2011; 18: 194-202.
23. Donnelly J, Medini D, Giuliani M, et al. Estimating the potential strain coverage in Europe of a multicomponent vaccine targeting serogroup B meningococci. 11th EMGM meeting; Ljubljana, Slovenia; May 18-20, 2011. Abstract O 08.
24. Dinleyici EC. Current status of pneumococcal vaccines: lessons to be learned and new insights. Exp Rev Vaccines 2010; 9: 1017-22.
25. Boisier P, Nicolas P, Djibo S, et al. Meningococcal meningitis: unprecedented incidence of serogroup X-related cases in 2006 in Niger. Clin Infect Dis 2007; 44: 657-63.
26. Beerninck PT, Caugent DA, Welsch JA, Koeberling O, Granoff DM. Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135, and X strains from Africa. J Infect Dis 2009; 199: 1360-68.
27. Marcy SM, Kohl KS, Dagan R, et al. Fever as an adverse event following immunization: case definition and guidelines of data collection, analysis, and presentation. Vaccine 2004; 22: 551-56.
28. McNicholas A, Galloway Y, Stehr-Green P, et al. Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006. Human Vaccines 2007; 3: 196-204.
29. Van de Berg BJ, Yerushamy J. Studies on convulsive disorders in young children. Pediatr Res 1969; 3: 298-304.
30. Verity CM, Bulter NR, Golding J. Febrile convulsion in a national cohort followed up from birth. I-Prevalence and recurrence in the first five years of life. BMJ 1985; 290: 1307-10.
31. Fischer TK, Holman RC, Yorita KL, Belay ED, Melbye M, Koch A. Kawasaki syndrome in Denmark. Pediatr Infect Dis J 2007; 26: 411-15.
32. Heuclin T, Dubos F, Hue V, et al. Increased detection rate of Kawasaki Disease using new diagnostic algorithm, including the early use of echocardiography. J Pediatr 2009; 155: 695-99.